We will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the solid organ donor. These 20 patients will be compared to 20 historical matched controls with regards to allogenic blood product usage and other physiologic markers
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Up to 4 units (each unit contains 350mL) of leukoreduced donor whole blood
Up to 350mL of Allogenic banked component blood transfusion in a 1:1:1 manner (packed red blood cells : plasma : platelets)
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Use of allogenic banked blood products
Measured by the number of allogenic banked blood products used
Time frame: perioperative up to 72 hours post operative
Economic cost
Total cost of perioperative transfusions
Time frame: perioperative up to 72 hours post operative
Number of Serious Adverse Events (SAEs)
Number of deaths, life-threatening events, hospitalizations, disabilities or permanent damage, or congenital anomalies
Time frame: Baseline to discharge (approximately 4-5 days)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.